Phil Meister

Phil Meister


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
PMPhil Meister
Phil Meister
HIHannes Irmer
Hannes Irmer
APAndreas Paul
Andreas Paul
DHDieter P. Hoyer
Dieter P. Hoyer
Purpose: Pyogenic liver abscess (PLA) is a collection of pus in the liver, often without a known direct cause. There is discord on the best diagnostic and therapeutic strategy. We aimed to examine these questions in our patient cohort. Methods: A total of 66 out of 309 patients with PLA at our tertiary referral center between 2012 and 2020 had a primarily unknown cause. We analyzed PLA configuration, comorbidities, and whether an underlying cause could be found later. Therapy was sorted by antibiotics alone, percutaneous drainage, and primary surgery. Success was assessed by a change of initial therapy, in-hospital mortality, and mean hospital stay. Results: Overall mortality was 18%; in 55%, a causative condition could be found. CRP, GGT, size, and multiple localization go along with higher mortality. Antibiotics alone had a failure rate of 82%. Percutaneous drainage was successful in 70% of cases. Surgery was mainly reserved for failed previous non-surgical treatment and had in-hospital mortality of 12%. Conclusions: PLA goes along with high mortality. In the majority of all patients, a causative condition can be identified by detailed diagnostics. Percutaneous drainage together with antibiotics is the therapy of choice and is successful in 70% of cases. If drainage is insufficient or impossible, surgery is an effective alternative.

12 June 2020 in Diseases
Verified
Journal Article
Open access
PDF file
PMPhil Meister
Phil Meister
CSChristian Steinke-Ramming
Christian Steinke-Ramming
MBMechthild Beste
Mechthild Beste
HLHenrike Lenzen
Henrike Lenzen
GGGuido Gerken
Guido Gerken
CJChristoph Jochum
Christoph Jochum
Background & Aims: The pathogenesis of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) remains unclear. The aim of this study was to reveal certain single nucleotide polymorphisms (SNP) in genes for regulatory proteins in the immunologic pathway possibly going along with susceptibility of attaining PBC or PSC. Methods: 126 patients with either PBC or PSC with clinical and laboratory data were enrolled in the study. SNPs in three genes (CTLA-4, ICOS, and FOX-P3) which are suspected to play a key role in the autoimmune pathway were analyzed to determine allele variants. Gene expression was measured by RealTime PCR using mRNA. Results: Patients with cirrhosis had a lower number of CTLA-4 copies than patients without cirrhosis (p = 0.04). Accordingly, patients with lower CTLA-4 copies had a poorer recovery of gamma-glutamyltransferase (GGT) in course of their disease (−69.8 U/l vs. −176.1 U/l p = 0.04). Two SNP allele variants (CTLA4 rs733618 and FOXP3 rs2280883) associated with low CTLA-4 expression could be determined. Patients having both variants showed worsening of GGT (−61.7 U/l vs. −132.6 U/l, p = 0.04) and a trend towards a more progressive disease in terms of cirrhosis. (24% vs. 13% p = ns). Conclusions: Low expression of CTLA-4 is associated with a more advanced disease in patients with PBC and PSC. Furthermore, we identified two SNP allele variants (CTLA4-SNP rs733618 and FOXP3-SNP rs2280883) associated with a lower CTLA-4 expression and possibly a more severe course of the diseases. Taken together, these results provide further evidence for the involvement of the immune system in the pathogenesis of these two cholestatic liver diseases. Lay summary: Primary biliary cholangitis and primary sclerosing cholangitis are chronic diseases of the bile ducts. Their cause remains widely unclear, but evidence suggests the immune system plays a central role. This study shows that gene alterations connected to the immune system might play a role in the course of the disease.

30 May 2025 in Colorectal Disease
Verified
Journal Article
Open access
PMPhil Meister
Phil Meister
SVSamira Vestweber
Samira Vestweber
JNJan Neuhaus
Jan Neuhaus
MRMarc A. Reschke
Marc A. Reschke
UNUlf Neumann
Ulf Neumann
ARAndreas Rink
Andreas Rink
Aim: The incidence of colorectal carcinoma (CRC) in transplant (TX) recipients is higher than in the general population. Registry data indicate inferior oncological outcomes for this population. While the general surgical risk is increased in TX recipients, the risk associated with elective CRC surgery in this population is not well investigated.Methods: TX recipients, who underwent elective surgical treatment for CRC at our specialized centre from 2008 to 2024 were included in this case–control study. The controls were randomly selected from our CRC database and matched according to tumour location and Charlson Comorbidity Index. Outcomes assessed included intensive care unit stay, in‐hospital mortality, length of hospital stay and major morbidity (defined as Clavien–Dindo Grade ≥3).Results: The study included 24 TX recipients. Ten patients had had either liver or kidney TX, three patients had undergone lung TX and one patient heart TX. The mean time interval between transplantation surgery and CRC was 8.82 years. Morbidity was significantly higher in the TX group (54.2% vs. 8.3%, P = 0.001; OR 13.0, 95% CI 2.5–68,1, P = 0.002) and length of hospital stay was significantly longer (25 vs. 9 days, P = 0.001; OR 9.09, 95% CI 1.4–16.7, P = 0.022) for TX patients. No significant differences in mortality and intensive care unit stay were observed.Conclusions: The risk of surgery for CRC in TX patients is significantly increased. Treatment decisions should involve TX experts to develop a tailored and considered treatment plan.

4 March 2026 in World Journal of Surgery
Verified
Journal Article
Open access
PMPhil Meister
Phil Meister
SVSamira Vestweber
Samira Vestweber
JNJan Neuhaus
Jan Neuhaus
MRMarc A. Reschke
Marc A. Reschke
UNUlf Neumann
Ulf Neumann
ARAndreas D. Rink
Andreas D. Rink
Background: Colorectal and small bowel surgery in transplant (TX) recipients presents unique perioperative challenges due to immunosuppression and comorbidities, with poorly defined risks. Methods: A retrospective analysis was conducted on 237 TX recipients who underwent colorectal or small bowel surgery at a specialized center between 2008 and 2024. Patient characteristics (transplant type, time since TX, immunosuppression, Charlson Comorbidity Index) and surgical details were analyzed in relation to postoperative outcomes (ICU stay, in‐hospital mortality, length of stay, major morbidity [Dindo‐Clavien ≥ 3]). Results: Most patients had prior kidney (45.6%) or liver TX (28.3%). The incidence of all adverse endpoints was significantly higher in emergencies as compared to elective surgery (mortality 25.6% vs. 6.2%, morbidity 52.3% vs. 35.4%, LOS 24.9d vs. 15.7d, ICU stay 10.7d vs. 2.9d; all p ≤ 0.001). 14.8% had surgical site infections, 9.7% cardiopulmonary complications. Primary anastomosis was not correlated with worse outcome. Multivariate regression showed emergency surgery (OR 8.48 (2.68–26.8) p = 0.001), colorectal surgery (OR 3.26 (1.54–6.90) p = 0.002) and heart TX (OR 4.35 (1.10–17.23) p = 0.036) as independent risk factors, patients receiving prednisolone had reduced risk (OR 0.28 (0.13–0.60) p = 0.001). Heart TX and emergency surgery correlated with longer ICU stay, hematopoetic stem cell transplantation with longer LOS. Conclusions: TX recipients undergoing colorectal or small bowel surgery face considerable perioperative risks, especially in emergency situations and after heart transplantation. The feasibility of primary anastomosis in selected patients suggests that surgical strategies should be tailored, emphasizing the need for specialized, multidisciplinary care to optimize outcomes in this vulnerable population.

11 January 2019 in Der Chirurg
Verified
Journal Article
Closed access
PDF file
PMPhil Meister
Phil Meister
JNJ. Neuhaus
J. Neuhaus
AVA. Vosschulte
A. Vosschulte
HDH. Dralle
H. Dralle

9 September 2026 in European Surgery
Verified
Journal Article
Open access
PDF file
MRMarc Alexander Reschke
Marc Alexander Reschke
SSSophia Schmitz
Sophia Schmitz
AGAnja Gallinat
Anja Gallinat
UNUlf Neumann
Ulf Neumann
PMPhil Meister
Phil Meister
Summary: Background: Gallbladder cancer (GBC) is a highly aggressive malignancy with a poor prognosis and varied global incidence. Despite surgical resection being the primary treatment, optimal approaches remain heterogeneous and debated due to limited high-quality evidence. This study aims to validate current surgical recommendations in a European real-world cohort. Methods: We retrospectively analyzed data from 150 GBC patients who underwent surgery at the University Hospital of Essen, Germany (2008–2023). Patient and tumor characteristics (UICC/TNM stage, incidental diagnosis, surgical approach), perioperative outcomes (mortality, morbidity, length of hospital stay), and overall survival (OS) were recorded. Congruence with established surgical recommendations was assessed, and its impact on OS analyzed using multivariate regression. Results: Our cohort, predominantly female (60%) with a mean age of 64.9 years, included 42% of incidental cases. Overall mortality was 6.3%, and morbidity was 24.6%. Curative intent resection was performed in 57% of patients. Major resections and extrahepatic bile duct resections were associated with higher perioperative risk. R0 resection, regardless of extent, yielded better OS than palliative treatment (21–27 months vs. 8.4 months p = 0.001). OS correlated with UICC stage (hazard ratio [HR] 2.23, p = 0.001). Importantly, noncongruence with surgical recommendations was significantly associated with worse OS (HR 5.1, p = 0.006). Conclusion: Our findings validate current recommendations for GBC surgery, emphasizing the importance of adherence to achieve optimal outcomes. Despite high morbidity in advanced resections, R0 status remains crucial. These data from a European cohort contribute to bolstering evidence for current surgical standards in GBC management.